Keryx Biopharmaceuticals, Inc. announced the publication of a post-hoc analysis of Auryxia phase 3 trial data for iron deficiency anemia in adult patients with chronic kidney disease (CKD), not on dialysis, in the online issue of the American Journal of Hematology. In the phase 3 study, 234 patients were randomized to receive ferric citrate (n=117) or placebo (n=117). The full results of the phase 3 study were published in January 2017 in the Journal of the American Society of Nephrology. This post-hoc analysis assessed the intent-to-treat population (ferric citrate, n=117; placebo, n=115). Baseline characteristics were similar across treatment groups. Results of this multivariable regression analysis show the following variables were associated with greater hemoglobin increases from baseline at 16 weeks: ferric citrate treatment (p<.0001), lower baseline hemoglobin (p=.0160), higher serum albumin (p=0.0007), lower intact fibroblast growth factor 23 (FGF23) (p=0.0024), and lower transferrin saturation (TSAT) (p=0.0189). Treatment interactions were observed for TSAT and ferritin only.